CAN IMMUNOME BOUNCE BACK FROM CLINICAL HOLD ON IMM-BCP-01 $IMNM
Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company, announced the receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) for its recently submitted Investigational New Drug (IND) for IMM-BCP-01, a three-antibody cocktail, intended for the treatment of SARS-CoV-2 (COVID-19).
Can Immunome bounce back from the temporary setback?
https://www.aviseanalytics.com/can-immunome-bounce-back-from-clinical-hold-on-imm-bcp-01/